Metlinka

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metlinka, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to lower elevated blood glucose levels.

GNH USA supplies Metlinka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metlinka combines metformin and sitagliptin to target the type 2 diabetes mellitus pathway, improving overall glycaemic control.

- Type 2 diabetes mellitus: reduces fasting and post‑prandial glucose levels, supporting long‑term metabolic management.

Metlinka may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild to moderate. - Decreased appetite: reduced food intake. - Hypoglycaemia (when combined with other glucose‑lowering agents): low blood sugar symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: inflammation of the pancreas. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic dysfunction: abnormal liver enzymes. - Persistent vomiting: may indicate serious gastrointestinal issue. - Severe hypoglycaemia: profound low blood glucose requiring emergency care.

Before initiating Metlinka, clinicians should consider several safety aspects.

- Renal function assessment: avoid or adjust dose in moderate to severe renal impairment. - Hepatic disease evaluation: use with caution in patients with liver dysfunction. - Cardiovascular status: monitor in patients with heart failure. - Concomitant medications: review for agents that may increase risk of hypoglycaemia. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Metlinka can interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure when combined with metformin. - Strong CYP2C9 inhibitors (e.g., fluconazole): increase metformin plasma concentrations. - Alcohol abuse: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened hypoglycaemia risk; monitor glucose levels. - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - Rifampicin: may reduce sitagliptin exposure. - Antacids containing aluminium or magnesium: may delay metformin absorption.